This Plain Language Summary of Publication article (PLSP) from Future Neurology, the MycarinG study, tested whether rozanolixizumab could better improve symptoms of generalized myasthenia gravis compared to a placebo. This rare autoimmune disease causes muscle weakness and fatigue, and current treatments don’t always work well or may have limiting side effects. Rozanolixizumab was given once a week for six weeks.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study’ and was published in the Lancet Neurology.

Visit The Lancet using the link to read the original article.